Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2006

01-12-2006 | Case Reports

Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern

Authors: David Aguiar Bujanda, Miguel Ángel Cabrera Suárez, Uriel Bohn Sarmiento, Santiago Quintero Pérez, José Aguiar Morales

Published in: Clinical and Translational Oncology | Issue 12/2006

Login to get access
Metadata
Title
Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern
Authors
David Aguiar Bujanda
Miguel Ángel Cabrera Suárez
Uriel Bohn Sarmiento
Santiago Quintero Pérez
José Aguiar Morales
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 12/2006
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-006-0157-y

Other articles of this Issue 12/2006

Clinical and Translational Oncology 12/2006 Go to the issue

Editorial

It is about time that spain launches a National Cancer Act?

Case Reports

Patient with resected anaplastic astrocytoma and an image suggestive of relapse

Research Articles

Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain

Case Reports

Intracranial germ cell tumor mimicking anorexia nervosa

Research Articles

Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer

Educational Series

New potential therapeutic targets to combat epithelial tumor invasion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits